Country: United States
Language: English
Source: NLM (National Library of Medicine)
clindamycin hydrochloride (UNII: T20OQ1YN1W) (clindamycin - UNII:3U02EL437C)
Rebel Distributors Corp
clindamycin hydrochloride
clindamycin hydrochloride 150 mg
ORAL
PRESCRIPTION DRUG
To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as describe
Clindamycin hydrochloride capsules are available in the following strengths, colors and sizes: 150 mg Turquoise blue opaque cap and light green body printed with “RX692” on cap and body in black ink. NDC 21695-033-12 Bottles of 12 NDC 21695-033-21 Bottles of 21 NDC 21695-033-28 Bottles of 28 NDC 21695-033-40 Bottles of 40 NDC 21695-033-60 Bottles of 60 NDC 21695-033-90 Bottles of 90 300 mg Turquoise blue opaque cap and turquoise blue opaque body printed with “RX693” on cap and body in black ink. NDC 21695-034-21 Bottles of 21 NDC 21695-034-30 Bottles of 30 Store at 20 - 25° C (68 - 77° F). (See USP Controlled Room Temperature).
Abbreviated New Drug Application
CLINDAMYCIN HYDROCHLORIDE- CLINDAMYCIN HYDROCHLORIDE CAPSULE REBEL DISTRIBUTORS CORP ---------- CLINDAMYCIN HYDROCHLORIDE CAPSULES WARNING PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH NEARLY ALL ANTIBACTERIAL AGENTS, INCLUDING CLINDAMYCIN, AND MAY RANGE IN SEVERITY FROM MILD TO LIFE-THREATENING. THEREFORE, IT IS IMPORTANT TO CONSIDER THIS DIAGNOSIS IN PATIENTS WHO PRESENT WITH DIARRHEA SUBSEQUENT TO THE ADMINISTRATION OF ANTIBACTERIAL AGENTS. Because clindamycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by _Clostridium difficile_ is one primary cause of "antibiotic- associated colitis". After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against _C. difficile_ colitis. Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of therapy with clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Clindamycin hydrochloride is the hydrated hydrochloride salt of clindamycin. Clindamycin is a semisynthetic antibiotic produ Read the complete document